GlassScriptPhysician profile
Henry M Prost
NPI 1841229812
$19,091.26
in general payments reported to CMS, 2019-2025
68 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,341 · 2020: $2,298 · 2021: $2,735 · 2022: $2,341 · 2023: $2,611 · 2024: $2,131 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,375 · Education: $1.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,375.48 |
| Education | $1.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,662.07 | 2019-2025 | |
| Lilly USA, LLC | $2,027.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,548.35 | 2019-2022 | |
| Novo Nordisk INC | $1,490.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $989.82 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $793.75 | 2019-2025 | |
| Amarin Pharma, INC. | $745.23 | 2019-2023 | |
| Amgen INC. | $590.41 | 2019-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $590.33 | 2019-2023 | Afrezza |
| Dexcom, INC. | $495.92 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.60 | 2019-2024 | Jardiance |
| Recordati_rare_diseases_inc. | $445.93 | 2021-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $414.80 | 2019-2025 | Licart, Tirosint, Tirosint |
| Insulet Corporation | $387.51 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $380.92 | 2021-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $379.43 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Xeris Pharmaceuticals, INC. | $367.83 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $348.89 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $254.75 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $203.86 | 2019-2025 | Korlym |
| Acella Pharmaceuticals, LLC | $197.88 | 2022-2025 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $185.86 | 2021-2025 | Strensiq |
| Beta Bionics, INC. | $181.23 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $179.44 | 2021-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $174.07 | 2023-2025 | Yorvipath |
| Sequel Med Tech, LLC | $159.07 | 2025 | Twiist |
| Cequr Corporation | $146.32 | 2022-2025 | Cequr Simplicity |
| Echosens North America, INC. | $119.24 | 2025 | Fibroscan |
| Madrigal Pharmaceuticals | $113.95 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $106.97 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $102.47 | 2019-2022 | |
| Becton, Dickinson and Company | $102.22 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $97.47 | 2024-2025 | |
| Radius Health, INC. | $96.04 | 2019-2023 | Tymlos |
| Ultragenyx Pharmaceutical INC. | $87.85 | 2020-2021 | |
| Nevro Corp. | $76.63 | 2023-2024 | Senza |
| Astellas Pharma US INC | $71.88 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $69.91 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $63.64 | 2019 | |
| Currax Pharmaceuticals LLC | $62.82 | 2020-2021 | |
| Avvisto Therapeutics, LLC | $62.14 | 2024-2025 | Cycloset |
| Lifescan, INC. | $61.45 | 2019-2021 | |
| Medtronic Minimed, INC. | $61.11 | 2019-2020 | |
| Tolmar, INC. | $58.84 | 2023 | |
| Shire North American Group INC | $57.30 | 2019 | |
| Vistapharm, INC. | $55.04 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $53.42 | 2023-2025 | Baqsimi |
| Pfizer INC. | $51.67 | 2022-2023 | |
| Intuity Medical INC | $50.99 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Zealand Pharma US, INC. | $47.23 | 2021 | |
| Vivus LLC | $47.09 | 2023-2024 | Qsymia |
| Halozyme INC | $42.78 | 2023 | |
| Glaxosmithkline, LLC. | $42.23 | 2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $39.94 | 2020 | |
| Alvogen INC | $39.71 | 2022-2023 | Teriparatide |
| Clarus Therapeutics INC. | $37.11 | 2021 | |
| Eusa Pharma (US) LLC | $34.12 | 2022 | |
| Bolton Medical INC | $29.76 | 2025 | Treo Abdominal Stent-Graft System |
| Companion Medical, INC. | $29.16 | 2020 | |
| Acerus Pharmaceuticals Corporation | $26.01 | 2020 | |
| Chiesi USA, INC. | $24.72 | 2024 | Mycapssa |
| Kyowa Kirin, INC. | $22.66 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.38 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.53 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.51 | 2025 | Azmiro |
| Amryt Pharma Holdings LTD | $17.10 | 2023 | Mycapssa |
| Alfasigma USA, INC. | $16.21 | 2021 | |
| Eisai INC. | $16.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Prost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.